Search Result

Isoforms Recommended:	RORγ

Results for "

ROR-γ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ROR (36) Apoptosis (2) Dihydroorotate Dehydrogenase (2) DNA/RNA Synthesis (1) Endogenous Metabolite (1) FXR (1) Interleukin Related (1) Isotope-Labeled Compounds (1) LXR (1) SARS-CoV (1)
By Research Areas:	Cancer (16) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (18) Metabolic Disease (1) Neurological Disease (3)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: ROR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-49076

RORγ inverse agonist 1	ROR	Cancer
RORγ inverse agonist 1 is the inverse agonist of RORγ .

HY-128573

RORγt Inverse agonist 3	ROR	Neurological Disease
RORγt Inverse agonist 3 is a potent, selective and orally active *RORγ* inverse agonist, with EC₅₀s of 0.22 μM and 0.15 μM for hRORγ and RORγt (human IL-17 cells), respectively .

HY-120210

XY018	ROR	Inflammation/Immunology Cancer
XY018 is a potent *ROR-γ*-selective antagonist. XY018 inhibits ROR-γ constitutive activity in 293T cells with high potency (EC₅₀, 190 nM). XY018 binds to the ROR-γ hydrophobic ligand binding domain (LBD) .

HY-132900

RORγ agonist 1	ROR	Cancer
RORγ agonist 1 is a potent and orally bioavailable *RORγ* agonist (EC₅₀ = 21 nM) with antitumor activity.

HY-155542

RORγ antagonist 1	ROR	Cancer
RORγ antagonist 1 (compound 22), a potent betulinic acid derivative, is an antagonist of *RORγ* (K_D=0.18 μM). RORγ antagonist 1 exhibits anti-proliferative activity in HPAF-II pancreatic cancer xenograft model. RORγ antagonist 1 inhibits RAS/MAPK and AKT/mTORC1 pathway, and induces caspase-dependent apoptosis in pancreatic cancer cells .

HY-169220S

RORγ/DHODH-IN-1	ROR Dihydroorotate Dehydrogenase DNA/RNA Synthesis Isotope-Labeled Compounds	Infection
RORγ/DHODH-IN-1 (compound 1404), a deuterium labeled compound, is a dual *RORγ* and DHODH inhibitor with IC₅₀ values of 9.7 nM and 100 nM, repaectively. RORγ/DHODH-IN-1 blocks the replication of SARS-CoV-2, HCMV, and non-enveloped DNA virus (HAdV5) .

HY-169222S

RORγ/DHODH-IN-2	Dihydroorotate Dehydrogenase ROR SARS-CoV	Infection
RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual inhibitor of RORγ/DHODH with IC₅₀ values of 11.9 nM and 90 nM, respectively. RORγ/DHODH-IN-2 exhibits antiviral activity by inhibiting the activity of SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC₅₀ values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively .

HY-129338

CID 7309015	ROR	Inflammation/Immunology
CID 7309015 is an inhibitor of retinoic acid-related orphan receptor gamma (ROR-γ). CID 7309015 can be used for research of inflammation, NF-κB signaling or inflammatory arthritis .

HY-155487

JTE-151	ROR	Neurological Disease Inflammation/Immunology
JTE-151 is a *RORγ* inhibitor, which can suppress overactive immune response through inhibition of RORγ related to the activation of Th17 cells, making JTE-151 possible to be used in autoimmune disease research .

HY-115777

ARN-6039	ROR	Neurological Disease
ARN-6039 is an orally available inverse agonist of *RORγ* for autoimmune demyelinating disease.

HY-104037A

Cintirorgon sodium LYC-55716 sodium	ROR	Cancer
Cintirorgon sodium is a first-in-class, selective and orally bioavailable *RORγ* agonist. Cintirorgon sodium (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival .

HY-104037

Cintirorgon 5+ Cited Publications LYC-55716	ROR	Cancer
Cintirorgon (LYC-55716) is a first-in-class, selective and orally bioavailable *RORγ* agonist. Cintirorgon (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival .

HY-16998

SR2211	ROR	Inflammation/Immunology
SR2211 is a potent, selective synthetic *RORγ* modulator and functions as an inverse agonist, with a K_i of 105 nM and an IC₅₀ of ~320 nM.

HY-111366

CD12681	ROR	Inflammation/Immunology
CD12681 (compound 14) is a potent and selective *RORγ* inverse agonist with IC₅₀ of 19 nM and 10 nM for RORγ GAL4 and CD4-IL-17 cells, respectively. CD12681 decreases the IL-17 inflammatory cell recruitment. CD12681 has the potential for the research of psoriasis .

HY-14422

SR1078 10+ Cited Publications	ROR	Cancer
SR1078 is a selective agonist of retinoic acid receptor-related orphan receptor α/γ (RORα/RORγ). SR1078 directly binds to the ligand binding domain of RORα and RORγ and increases the transcriptional activity of these receptors, leading to stimulation of RORα/γ target gene transcription .

HY-115879

SHR168442	ROR	Inflammation/Immunology Cancer
SHR168442 is a modulator of retinoid-related orphan receptor gamma (RORγ) with an IC₅₀ value of 0.035 μM.

HY-148237

JNJ-54119936	ROR	Inflammation/Immunology
JNJ-54119936 is a novel RORγ (RORc) inverse agonist (K_d=5.3 nM) .

HY-19774

GNE-0946	ROR	Inflammation/Immunology
GNE-0946 is a potent and selective RORγ( RORc) agonist with an EC₅₀ value of 4 nM for HEK-293 cell.

HY-128604

XY101	ROR	Cancer
XY101 is a potent, selective, metabolically stable and orally available *RORγ* inverse agonist with an IC₅₀ of 30 nM and a K_d of 380 nM .

HY-145590

Retezorogant	ROR	Cancer
Retezorogant is a retinoid-related orphan receptor γ (RORγ) antagonist, extracted from patent WO2016093342 A1.

HY-100084

Methyl-3β-hydroxycholenate	ROR	Inflammation/Immunology
Methyl-3β-hydroxycholenate is a *ROR gamma* modulator extracted from patent US20110263046 A1, in figure 2.

HY-19770

GSK2981278 3 Publications Verification	ROR	Inflammation/Immunology
GSK2981278 is a potent and selective *RORγ* inverse agonist. GSK2981278 inhibits activation of the il17 promoter and interferes RORγ-DNA binding .

HY-120384

AZD-0284 2 Publications Verification	ROR	Inflammation/Immunology
AZD-0284 is a selective inverse agonist of the nuclear receptor *RORγ*. AZD-0284 has the potential for plaque psoriasis vulgaris and respiratory tract disorders treatment .

HY-163612

XY077	ROR Apoptosis	Cancer
XY077 (compound 14a) is a *RORγ* inverse agonist with the IC₅₀ of 0.004 μM. XY077 induces cell apoptosis and shows antiproliferative activity in vivoand in vitro .

HY-163611

XY039	ROR	Cancer
XY039 (compound 13e) is a *RORγ* inverse agonist with the IC₅₀ of 0.55 μM. XY039 induces cell apoptosis and shows antiproliferative activity in vivoand in vitro .

HY-113345

Zymostenol 5a-Cholest-8-en-3b-ol	Endogenous Metabolite ROR	Cancer
Zymostenol (5a-Cholest-8-en-3b-ol) is a late-stage precursor in the biosynthesis of cholesterol. Zymostenol is a *RORγ* agonist (EC₅₀: 1 μM) .

HY-19775

GNE-6468	ROR	Inflammation/Immunology
GNE-6468 is a highly potent and selective RORγ (RORc) inverse agonist with an EC₅₀ value of 13 nM for HEK-293 cell. GNE-6468 exhibits an EC₅₀ of 30 nM for IL-17 PBMC .

HY-163192

W6134	ROR	Cancer
W6134 is highly potent and selective *RORγ* covalent inhibitor with IC₅₀ of 0.21 μM. W6134 exhibits superior activity ini nhibiting the proliferation and colony formation and inducing apoptosis. W6134 can be used for the research of cancer .

HY-16983

GNE-3500	ROR	Inflammation/Immunology
GNE-3500 is a selective, orally active antagonist for Retinoic Acid Receptor-Related Orphan Receptor C (RORc, also known as *RORγ* or NR1F3) with an EC₅₀ of 12 nM. GNE-3500 exhibits good pharmacokinetic characteristics in rats .

HY-152851

Izumerogant IMU-935	ROR	Others Cancer
Izumerogant (IMU-935) is an inverse agonist of retinoid-related orphan receptor-gamma (RORγ). Izumerogant (compound 123) also potently inhibits IL-17A, IL-17F and IFN-γ activity with IC₅₀s <50 nM .

HY-12776

GSK805 3 Publications Verification	ROR	Inflammation/Immunology
GSK805 is an orally active and CNS penetrant RORγt inhibitor. GSK805 inhibits RORγ and Th17 cells differentiation with pIC₅₀ values of 8.4 and >8.2. GSK805 inhibits the function of Th17 cells. GSK805 can be used for the research of immunity .

HY-120785

SR1555	ROR	Inflammation/Immunology
SR1555 is a specific retinoic acid receptor-related orphan nuclear receptor γ (RORγ) inverse agonist with an IC₅₀ value of 1 μM. SR1555 not only inhibits TH17 cell development and function but also increases the frequency of T regulatory cells, as well as inhibits the expression of IL-17. SR1555 can be used for researching autoimmune diseases .

HY-10626

T0901317 Maximum Cited Publications 28 Publications Verification	LXR FXR ROR Apoptosis	Cardiovascular Disease Metabolic Disease Cancer
T0901317 is an orally active and highly selective LXR agonist with an EC₅₀ of 20 nM for LXRα . T0901317 activates FXR with an EC₅₀ of 5 μM . T0901317 is RORα and *RORγ* dual inverse agonist with K_i values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .

HY-120785A

SR1555 hydrochloride	ROR	Inflammation/Immunology
SR1555 hydrochloride is the hydrochloride salt form of SR1555 (HY-120785). SR1555 hydrochloride is an inverse agonist for retinoic acid receptor-related orphan nuclear receptor γ (RORγ) with an IC₅₀ of 1 μM. SR1555 hydrochloride inhibits the development and function of pro-inflammatory TH17 cell, increases the frequency of anti-inflammatory T regulatory (Treg) cells. SR1555 hydrochloride can be used for research about autoimmune diseases .

HY-126252

A-9758	ROR Interleukin Related	Inflammation/Immunology
A-9758 is a RORγ ligand and a potent, selective RORγt inverse agonist (IC₅₀=5 nM), and exhibits robust potency against IL-17A release. A-9758 is effective in suppressing both Th17 differentiation and Th17 effector function. A-9758 significantly attenuates IL-23 driven psoriasiform dermatitis and is effective in blocking skin and joint inflammation .

HY-126037

(±)-ML 209 1 Publications Verification	ROR	Inflammation/Immunology
(±)-ML 209 (compound 4n), a diphenylpropanamide, is a retinoic acid-related orphan receptor *RORγ* antagonist with an IC₅₀ of 1.1 μM. (±)-ML 209 inhibits RORγt transcriptional activity with an IC₅₀ of 300 nM in HEK293t cells. (±)-ML 209 inhibits the transcriptional activity of RORγt, but not RORα in cells. (±)-ML 209 selectively inhibits murine Th17 cell differentiation without affecting the differentiation of naïve CD4 ⁺ T cells into other lineages, including Th1 and regulatory T cells .

Cat. No.	Product Name	Chemical Structure

HY-169220S

RORγ/DHODH-IN-1
RORγ/DHODH-IN-1 (compound 1404), a deuterium labeled compound, is a dual *RORγ* and DHODH inhibitor with IC₅₀ values of 9.7 nM and 100 nM, repaectively. RORγ/DHODH-IN-1 blocks the replication of SARS-CoV-2, HCMV, and non-enveloped DNA virus (HAdV5) .

HY-169222S

RORγ/DHODH-IN-2
RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual inhibitor of RORγ/DHODH with IC₅₀ values of 11.9 nM and 90 nM, respectively. RORγ/DHODH-IN-2 exhibits antiviral activity by inhibiting the activity of SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC₅₀ values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: